Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $22.00.
OLMA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Tuesday, June 4th. The Goldman Sachs Group initiated coverage on shares of Olema Pharmaceuticals in a report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 target price on the stock.
Check Out Our Latest Stock Report on OLMA
Olema Pharmaceuticals Price Performance
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). On average, equities research analysts forecast that Olema Pharmaceuticals will post -2.3 earnings per share for the current fiscal year.
Insider Transactions at Olema Pharmaceuticals
In other news, Director Cyrus Harmon sold 5,000 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $12.26, for a total transaction of $61,300.00. Following the completion of the transaction, the director now owns 756,283 shares in the company, valued at $9,272,029.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 50,000 shares of company stock worth $527,100. Insiders own 19.40% of the company’s stock.
Hedge Funds Weigh In On Olema Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $8,854,000. Swiss National Bank bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $906,000. Perceptive Advisors LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $7,574,000. Dimensional Fund Advisors LP grew its position in Olema Pharmaceuticals by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,715,420 shares of the company’s stock valued at $24,069,000 after buying an additional 21,420 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in Olema Pharmaceuticals by 879.6% in the 4th quarter. Victory Capital Management Inc. now owns 621,527 shares of the company’s stock valued at $8,720,000 after buying an additional 558,077 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
- Five stocks we like better than Olema Pharmaceuticals
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Survey: Top 175 Fittest Retirement Locations in America
- The Role Economic Reports Play in a Successful Investment Strategy
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Insider Trading – What You Need to Know
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.